EG S.p.A. (Stada Group)

What EG S.p.A. (Stada Group) does

EG S.p.A., operating commercially as EG STADA Italia, is the Italian subsidiary of STADA Arzneimittel AG, a German pharmaceutical group founded in 1895 in Dresden and listed on the Frankfurt Stock Exchange (ticker: STDA). The Italian entity operates three product segments: (i) Generics (Farmaci Equivalenti) — off-patent drugs containing the same active ingredient, dose, efficacy and safety as branded reference medicines, reimbursed through the Italian National Health Service (SSN / Servizio Sanitario Nazionale); (ii) Consumer Healthcare — an over-the-counter portfolio of heritage brands including Nizoral (antidandruff), Venoruton (venous circulation), Hirudoid (topical bruise care), Hedrin (head lice), Duofilm (warts), Lenirit (skin), Lisomucil (mucolytic), Lactease, and others; and (iii) Specialty & Biosimilars — biological and innovative therapies in oncology, inflammatory bowel disease, neurology (Parkinson's), and nephrology (IgA nephropathy). At the parent level, STADA Group reported 2025 adjusted revenues of EUR 4.3 billion (+6% YoY) and adjusted EBITDA of EUR 961 million (+8% at constant FX), with the Specialty segment crossing EUR 1 billion for the first time and biosimilars growing 17%.

The business runs a multi-channel operating model anchored in Italy's pharmacy network (~3,000 pharmacies in Lombardy alone), serviced by a dedicated field force of ISF (Informatori Scientifici del Farmaco — medical sales representatives) and a 'Linea Unica Farmacia' commercial division. Specialty and biosimilar products are supported by Medical Science Liaisons (MSL) engaging medical specialists and scientific societies (e.g., LIMPE-DISMOV for neurology). Product economics depend on regulated AIFA pricing/reimbursement for SSN-reimbursed generics, retail OTC pricing for consumer healthcare, and tender/hospital channels for specialty and biosimilars. The parent group expanded its pipeline by in-licensing 110 new products globally during 2025, indicating an asset-light growth model that EG Italia inherits in its territory.

Beyond commercial operations, EG STADA operates sizeable corporate-health initiatives used as brand and stakeholder-engagement assets: the STADA Health Report (an annual pan-European survey of ~20,000 respondents, conducted since 2022), the Tour della Salute mobile prevention program (65,000+ free medical consultations since 2018, expanding to 15 Italian cities in 2026), the Insieme in Salute phygital editorial platform, and partnerships with Federfarma Lombardia, Fondazione Francesca Rava, Cittadinanzattiva, Banco Farmaceutico, and Università Cattolica. Salvatore Butti serves as General Manager & Managing Director. Sustainability positioning is anchored by STADA Group's reported 36% reduction in carbon emissions vs. a 2020 baseline.

Name

EG S.p.A. (Stada Group)

Legal name

EG S.p.A.

Website

https://eglab.it

Company type

Private

Founded year

1895

Operating status

Operating

Headcount range

1–10 employees

Short description

EG S.p.A. (Stada Group) is the Italian subsidiary of Germany's STADA Group, distributing generic drugs reimbursed by the Italian NHS, an OTC Consumer Healthcare portfolio of heritage brands (Nizoral, Venoruton, Hirudoid, Hedrin, Duofilm), and biosimilar/specialty medicines to Italian pharmacies, physicians, and the SSN.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro industry

PRIMARYHLAIABAL

Generic Hospital & Institutional Products

Healthcare & Life Sciences/Pharmaceuticals/Generic Pharmaceuticals

SECONDARYHLAIAAAA

Primary Care & General Medicine Pharmaceuticals

Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

• Generic pharmaceuticals
• Consumer healthcare
• Biosimilar medicines
• Pharmacy distribution
• Specialty therapeutics

Headquarters

HQ city

Milan, Lombardy

HQ country

Italy

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Personnel, Marketing or Sales, Supply Chain, Operations, Technology or R&D

Revenue model

1. Generic/Equivalent Pharmaceuticals (Generics): EG STADA's historic core business. Produces and distributes generic/equivalent drugs containing the same active ingredient, in the same quantity, as branded reference medicines. These are sold through pharmacies and the National Health Service (SSN) in Italy, providing accessible and cost-effective therapeutic alternatives.
2. Consumer Healthcare (OTC): Over-the-counter products for health and wellness sold directly to consumers via pharmacies. Includes brands such as Nizoral, Nizoral Care, Venoruton, Hirudoid, Hedrin, Lenirit, and others addressing conditions from skin care to hair care, respiratory relief, and nutritional supplements.
3. Specialty & Biosimilars: Biosimilar and specialty pharmaceutical products, including innovative therapies in areas such as oncology, inflammatory bowel diseases (IBD), neurology (Parkinson's), and nephrology (IgA Nephropathy). The Specialty segment exceeded EUR 1 billion in revenues for the first time in 2025, with biosimilars growing 17%.

Go-to-market motion2 records

Distribution channels5 records

Marketing channels8 records

Core offering

EG S.p.A. (operating as EG STADA Italia) is the Italian subsidiary of the German pharmaceutical group STADA Arzneimittel AG. The company manufactures and distributes three core product lines in Italy: generic equivalent drugs (Farmaci Equivalenti), Consumer Healthcare OTC products (brands including Nizoral, Venoruton, Hirudoid, Hedrin, Duofilm, Lenirit, Lactease), and specialty/biosimilar pharmaceuticals for oncology, neurology, nephrology and inflammatory diseases. Products are sold primarily through the Italian pharmacy network and the national health service (SSN), supported by a national field sales force, medical science liaisons, and pharmacy education programs.

Product overview

EG S.p.A. (Stada Group) operates as a pharmaceutical company with three core business segments: Generic Drugs (Farmaci Equivalenti), Consumer Healthcare, and Biosimilars/Specialty products. The product portfolio includes branded Consumer Healthcare products such as Nizoral (anti-dandruff), Venoruton (circulation), Hirudoid (bruise care), Hedrin (lice treatment), Duofilm (wart treatment), Lenirit (skin), Lactease (lactose intolerance), and others. The company also distributes generic equivalent drugs and biosimilar/specialty pharmaceuticals. Key initiatives include the STADA Health Report (annual pan-European health survey) and Tour della Salute (mobile health screening program).

Differentiator

Problem solved

Functional benefit

Brands

• Insieme in Salute: Phygital editorial project dedicated to patients and caregivers for health topics including prevention, lifestyle, and health information
• Tour della Salute
• STADA Health Report
• Venoruton
• Hirudoid
• Nizoral
• Nizoral Care
• Duofilm
• Lenirit
• Hedrin
• Lisomucil
• Lisonatural
• Ketodol
• Simecrin
• Zolemer
• Daosin
• GlutoSin
• Lactease
• Ergovis
• Sedatol
• Reidrax

Products and services

• Farmaci Equivalenti (Generic Drugs) Generic medicines containing the same active ingredient in the same dosage as branded reference drugs, providing effective and safe therapy at lower cost for Italian patients via the SSN and pharmacy channel.
• Consumer Healthcare (OTC) Over-the-counter products addressing everyday health and wellness needs, distributed through pharmacies to Italian consumers. Includes brands such as Nizoral, Venoruton, Hirudoid, Hedrin, Duofilm, Lenirit, Lactease, Sedatol, Ergovis, and others.
• Biosimilars and Specialty Pharmaceuticals Biological drugs and specialty therapies for complex conditions including oncology, inflammatory bowel disease (IBD), neurology (Parkinson's), and nephrology (IgA Nephropathy), expanding access to advanced therapies in Italy.
• Nizoral / Nizoral Care Anti-dandruff shampoo and oily-scalp hair care products including Nizoral Care Shampoo Cute Grassa and Nizoral Care Balsamo (conditioner), sold through Italian pharmacies.
• Venoruton OTC product for venous circulation support, sold through Italian pharmacies.
• Hirudoid Topical OTC product for bruise and circulation care sold through Italian pharmacies.
• Hedrin OTC head lice treatment product sold through Italian pharmacies.
• Duofilm OTC wart treatment product sold through Italian pharmacies.
• Lenirit OTC dermatological product for skin conditions, sold through Italian pharmacies.
• Eurax OTC topical product for skin itching and irritation relief sold through Italian pharmacies.
• Cerumol OTC ear wax removal solution sold through Italian pharmacies.
• Lisomucil Mucolitico Mucolytic OTC product for respiratory conditions sold through Italian pharmacies.
• Lisonatural OTC natural product line for respiratory care sold through Italian pharmacies.
• Ketodol OTC pain relief product sold through Italian pharmacies.
• Zolemer OTC product for gastrointestinal conditions sold through Italian pharmacies.
• Simecrin OTC product for digestive health sold through Italian pharmacies.
• Daosin OTC product for food intolerance support sold through Italian pharmacies.
• GlutoSin OTC product for gluten sensitivity/celiac support sold through Italian pharmacies.
• Lactease OTC product for lactose intolerance support sold through Italian pharmacies.
• Ergovis OTC product for musculoskeletal/ergogenic support sold through Italian pharmacies.
• Sedatol OTC product for sleep and relaxation support sold through Italian pharmacies.
• Reidrax OTC product for hydration support sold through Italian pharmacies.

Quantifiable outcome

• Over 70,000 free health screenings performed through Tour della Salute in recent years
• +3 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Six partnerships are on record, tiered core and minor.

• Federfarma LombardiacoreStrategic or Co-development Partner · 1 January 2026Federfarma Lombardia is the regional federation of pharmacy owners in Lombardy. EG STADA partnered with Federfarma Lombardia to support 'Progetto Mimosa Lombardia', an initiative to build a stable network between pharmacies, healthcare professionals, institutions, and associations to develop prevention, listening, and support models for women victims of violence. With 3,000 pharmacies in Lombardy, this partnership leverages pharmacy proximity to detect fragility and unmet needs.
• Associazione Farmaciste InsiemecoreStrategic or Co-development Partner · 1 January 2026EG STADA collaborates with Associazione Farmaciste Insieme as part of the Progetto Mimosa Lombardia initiative, which aims to create effective pathways of listening, guidance, and protection for women experiencing fragility and violence. The association contributes pharmacist expertise and a network of female pharmacy professionals.
• BANCO FARMACEUTICO - Fondazione ETScoreStrategic or Co-development Partner · 1 January 2026EG STADA supports the annual 'Giornate di Raccolta del Farmaco' (Medicine Collection Days) organized by Banco Farmaceutico, a solidarity campaign held in over 6,000 Italian pharmacies to provide medicines to people in economic hardship. EG STADA employees volunteer at collection points, and the company provides unconditional support to the initiative. In 2026, the campaign sought over 1.2 million medicines to support 500,000+ people, including 145,000 minors.
• Fondazione Francesca Rava - NPH Italia ETScoreStrategic or Co-development Partner · 1 January 2026EG STADA supports the 'In Farmacia per i Bambini' (In Pharmacy for Children) initiative organized by Fondazione Francesca Rava - NPH Italia ETS, which addresses healthcare poverty among minors in Italy. According to ISTAT 2024, 13.8% of minors live in absolute poverty (~1.28 million children), with 26.7% at risk of poverty or social exclusion.
• CittadinanzattivacoreStrategic or Co-development Partner · 1 January 2026EG STADA supports 'IoEquivalgo', a multi-year information and awareness campaign on generic medicines promoted by Cittadinanzattiva since 2016. The initiative provides citizens and healthcare professionals with clear, accessible tools to make informed therapeutic choices. It includes the website www.ioequivalgo.it, a mobile app, and in-person events in communities, squares, universities, and institutions across Italy.
• Università Cattolica del Sacro Cuore di MilanominorStrategic or Co-development Partner · 1 January 2026EG STADA engages with Università Cattolica del Sacro Cuore di Milano through student outreach programs. Martina Seghizzi (EG STADA) returned to her alma mater to speak with third-year Logistics & Operations students about her professional journey and the company's supply chain operations in the healthcare sector.

Scale indicators9 records

Expansion highlights6 records

Broad incumbents

• Menarini Group: Italian multinational pharmaceutical company headquartered in Florence. Overlaps with EG STADA in Italian consumer healthcare and specialty distribution through pharmacy channels, though broader in therapeutic areas.
• Angelini Pharma: Italian private pharmaceutical group with broad portfolio across consumer healthcare, branded pharma, and specialty. Operates a wider portfolio than EG STADA's niche but overlaps in OTC and prescription segments across Italy.
• Zambon Company: Italian family-owned pharmaceutical group with respiratory, pain, and consumer healthcare franchises. Overlaps with EG STADA in Italian OTC and prescription distribution through pharmacy networks, particularly in respiratory (Lisomucil vs. Zambon equivalents).
• Chiesi Farmaceutici: Italian private pharmaceutical group with strong respiratory, neonatology, and rare disease focus. Indirect peer through Italian pharmacy-channel presence and biosimilar/specialty ambitions overlapping with EG STADA's Specialty segment.
• Recordati S.p.A. Italian mid-cap pharmaceutical group (BIT: REC) with Italian and international presence in rare diseases and specialty. Peer to EG STADA through Italian pharmacy distribution and growing biosimilar/specialty portfolio.

Direct peers

• Doc Generici: Italian generic pharmaceuticals company focused on equivalent drugs distributed through the Italian pharmacy network. Direct competitor to EG STADA's generics segment with similar SSN reimbursement model and pharmacy channel focus in Italy.
• Viatris Italia (formerly Mylan): Italian subsidiary of Viatris, formed by the Mylan-Upjohn merger. Direct competitor in Italian generics and branded generics with similar product portfolio and pharmacy network distribution.
• Aurobindo Pharma Italia: Indian-headquartered generics manufacturer with significant Italian operations. Competes with EG STADA in the Italian generics market, particularly on price-sensitive SSN-reimbursed products.
• Teva Italia: Italian subsidiary of Teva Pharmaceutical Industries, one of the world's largest generic drug manufacturers. Competes directly with EG STADA across generics, specialty, and increasingly biosimilars in the Italian market.
• Sandoz Italia: Italian operations of Sandoz, the Novartis generics and biosimilars spin-off. Direct peer in Italian generics and biosimilars with comparable pharmacy-channel distribution and SSN reimbursement exposure.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/eg-s.p.a.-stada-group-

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about EG S.p.A. (Stada Group)